Avalo Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 12, 2024 and accepted by EDGAR at Aug 12, 2024, 07:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $343.0k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $263.0k | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$9.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$42.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $7.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | $14.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $98.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$22.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$14.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | −$30.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $4.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$24.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 7,653,302 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 4,402,640 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$22.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-06-30 | $93.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $95.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $108.3m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $96.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $110.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | −$13.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-036591. Last ingested by Listed: Oct 29, 2026, 16:18 ET. Listed shows no prices and gives no investment advice.